Similarly, AML patients with reduced expression of NK cell activating receptors such as NKp46 or NKp30 also have worse clinical outcomes [28,29], while patients expressing higher amounts of these receptors have better outcomes [30,31]. This evidence concerns the gene NCR2 and acute myeloid leukemia.